A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 17,800 shares of MYGN stock, worth $440,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,800
Previous 22,000 19.09%
Holding current value
$440,728
Previous $421,000 9.98%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $73,878 - $99,078
-4,200 Reduced 19.09%
17,800 $379,000
Q4 2023

Feb 14, 2024

SELL
$13.91 - $21.32 $133,536 - $204,672
-9,600 Reduced 30.38%
22,000 $421,000
Q3 2023

Nov 14, 2023

BUY
$15.99 - $23.22 $161,499 - $234,522
10,100 Added 46.98%
31,600 $506,000
Q2 2023

Aug 14, 2023

SELL
$17.56 - $23.76 $57,947 - $78,408
-3,300 Reduced 13.31%
21,500 $498,000
Q1 2023

May 15, 2023

SELL
$15.26 - $23.75 $123,606 - $192,375
-8,100 Reduced 24.62%
24,800 $576,000
Q4 2022

Feb 14, 2023

SELL
$14.51 - $20.99 $34,824 - $50,375
-2,400 Reduced 6.8%
32,900 $477,000
Q3 2022

Nov 14, 2022

SELL
$18.21 - $27.88 $122,007 - $186,796
-6,700 Reduced 15.95%
35,300 $674,000
Q2 2022

Aug 15, 2022

SELL
$16.45 - $25.88 $258,265 - $406,316
-15,700 Reduced 27.21%
42,000 $763,000
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $437,531 - $540,593
-19,300 Reduced 25.06%
57,700 $1.45 Million
Q4 2021

Feb 14, 2022

SELL
$24.13 - $32.63 $1.22 Million - $1.65 Million
-50,500 Reduced 39.61%
77,000 $2.13 Million
Q3 2021

Nov 15, 2021

SELL
$29.97 - $36.66 $7.69 Million - $9.41 Million
-256,700 Reduced 66.81%
127,500 $4.12 Million
Q2 2021

Aug 16, 2021

SELL
$25.39 - $32.61 $5.42 Million - $6.96 Million
-213,400 Reduced 35.71%
384,200 $11.7 Million
Q1 2021

May 17, 2021

SELL
$19.92 - $31.6 $2.6 Million - $4.13 Million
-130,700 Reduced 17.95%
597,600 $18.2 Million
Q4 2020

Feb 16, 2021

SELL
$12.16 - $19.77 $1.56 Million - $2.54 Million
-128,300 Reduced 14.98%
728,300 $14.4 Million
Q3 2020

Nov 16, 2020

BUY
$11.25 - $14.75 $2.69 Million - $3.52 Million
238,700 Added 38.63%
856,600 $11.2 Million
Q2 2020

Aug 14, 2020

BUY
$10.69 - $16.49 $5.47 Million - $8.43 Million
511,500 Added 480.73%
617,900 $7.01 Million
Q1 2020

May 15, 2020

BUY
$9.78 - $29.53 $1.04 Million - $3.14 Million
106,400 New
106,400 $1.52 Million
Q3 2019

Nov 14, 2019

SELL
$22.08 - $47.08 $262,752 - $560,252
-11,900 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$22.67 - $35.0 $269,773 - $416,500
11,900 New
11,900 $331,000
Q1 2019

May 15, 2019

SELL
$26.93 - $34.7 $210,054 - $270,660
-7,800 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$27.23 - $45.56 $212,394 - $355,368
7,800 New
7,800 $227,000
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $269,119 - $389,568
-9,698 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $7.8 Million - $11.1 Million
-270,614 Reduced 96.54%
9,698 $287,000
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $6.45 Million - $8.41 Million
-226,548 Reduced 44.7%
280,312 $9.63 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $12.2 Million - $18.3 Million
506,860
506,860 $18.3 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $2B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.